CaixaBank Expands Strategic Collaboration with Google Cloud to Accelerate AI and Data Capabilities

Caixabank has hired Morgan Stanley to evaluate a potential acquisition of Cetelem’s Spanish and Portuguese consumer lending operations, according to Expansion. The deal, valued between €900 million and €1 billion, would expand Caixabank’s consumer lending business. BNP Paribas initiated the sale as part of a strategic refocusing effort. All parties declined to comment.

Caixabank SA stock rose 1.1% to €13.12 after UBS upgraded it to Buy with a €14.90 price target, citing its potential in a higher ECB rate environment. JPMorgan also raised its target to €14.20. The stock had declined 1.3% previously, and analysts expect strong Q3 2026 earnings.

Johnson & Johnson (JNJ) reported that its experimental prostate cancer drug, JNJ-6143, showed promising results in an early-stage trial. Among 31 patients, 77% saw PSA reductions of at least 50%. The drug was acquired via JNJ's $3.05B purchase of Halda Therapeutics. Further testing is needed to confirm long-term effectiveness and safety.

Johnson & Johnson reported positive early-stage trial results for its prostate cancer drug JNJ-6143, acquired via a $3.05B deal. In 31 patients, 77% saw PSA levels drop by 50%+, with 69% showing tumor shrinkage. Side effects included nausea and elevated cholesterol. Data was presented at the European Society for Medical Oncology Congress.

Celcuity Inc. (CELC) announced new data from the VIKTORIA-1 study showing that its drug gedatolisib, combined with other treatments, improved progression-free survival in patients with HR+/HER2- breast cancer. The study found median PFS of 21.5 months for the triplet therapy in patients without liver metastases, compared to 9.1 months for the control group. The data was presented at the ESMO Congress 2026.

Zymeworks Inc. (ZYME) presented Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate, at ESMO Congress 2026. The study showed a 64.5% objective response rate in high-grade serous platinum-resistant ovarian cancer patients at the 6.4 mg/kg dose, with a favorable tolerability profile. The company plans to continue clinical development and is exploring strategic partnerships. A conference call is scheduled for October 27, 2026.